173 related articles for article (PubMed ID: 26004158)
1. Does enzyme replacement therapy enhance brain-derived neurotrophic factor expression in Gaucher disease?
Vairo F; Sperb-Ludwig F; Wilke M; Michellin-Tirelli K; Netto C; Camargo Neto E; Schwartz IV
J Neuroimmunol; 2015 Jun; 283():63. PubMed ID: 26004158
[No Abstract] [Full Text] [Related]
2. Does enzyme replacement therapy enhance brain-derived neurotrophic factor expression in Gaucher disease?
Agilli M; Ekinci S; Fidan G
J Neuroimmunol; 2015 Feb; 279():39. PubMed ID: 25669998
[No Abstract] [Full Text] [Related]
3. Brain-derived neurotrophic factor expression increases after enzyme replacement therapy in Gaucher disease.
Vairo F; Sperb-Ludwig F; Wilke M; Michellin-Tirelli K; Netto C; Neto EC; Doederlein Schwartz IV
J Neuroimmunol; 2015 Jan; 278():190-3. PubMed ID: 25468270
[TBL] [Abstract][Full Text] [Related]
4. Velaglucerase alfa, a human recombinant glucocerebrosidase enzyme replacement therapy for type 1 Gaucher disease.
Pastores GM
Curr Opin Investig Drugs; 2010 Apr; 11(4):472-8. PubMed ID: 20336596
[TBL] [Abstract][Full Text] [Related]
5. [Enzyme replacement therapy in adult patients with type I Gaucher disease].
Ponomarev RV; Lukina EA
Ter Arkh; 2019 Jul; 91(7):127-131. PubMed ID: 32598746
[TBL] [Abstract][Full Text] [Related]
6. [Advances in the specific treatments of Gaucher disease].
Meng Y
Zhonghua Nei Ke Za Zhi; 2024 Jul; 63(7):702-711. PubMed ID: 38951097
[TBL] [Abstract][Full Text] [Related]
7. Enzyme Replacement Therapy in a Gaucher Family.
Erdem N; Buran T; Berber I; Aydogdu I
J Natl Med Assoc; 2018 Aug; 110(4):330-333. PubMed ID: 30126557
[TBL] [Abstract][Full Text] [Related]
8. [Gaucher Disease].
Okuyama T
Brain Nerve; 2015 Sep; 67(9):1109-13. PubMed ID: 26329151
[TBL] [Abstract][Full Text] [Related]
9. Markers of coagulation activation and enhanced fibrinolysis in Gaucher type 1 patient: Effects of enzyme replacement therapy.
Mitrovic M; Sumarac Z; Antic D; Bogdanovic A; Elezovic I; Vukosavljevic D; Ignjatovic S; Majkic-Singh N; Suvajdzic N
Blood Cells Mol Dis; 2012 Jun; 49(1):58-9. PubMed ID: 22459893
[No Abstract] [Full Text] [Related]
10. EVALUATION OF EFFICIENCY OF IMIGLUCERASE (CEREZYME) IN THE TREATMENT OF GAUCHER DISEASE (CASE REPORTS AND REVIEW OF THE LITERATURE).
Samohalska O; Kornaga S; Mandziy Z; Boiko T; Radetska L
Georgian Med News; 2018 Feb; (Issue):69-73. PubMed ID: 29578427
[TBL] [Abstract][Full Text] [Related]
11. Gaucher disease and β-thalassemia: A rare coinheritance.
Makis A; Tzoufi M; Pappa E; Kyrochristos I; Zikou A; Xydis V; Argyropoulou MI; Chaliasos N
Blood Cells Mol Dis; 2017 Jun; 65():35-37. PubMed ID: 28458077
[No Abstract] [Full Text] [Related]
12. Development of a panel of highly sensitive, equivalent assays for detection of antibody responses to velaglucerase alfa or imiglucerase enzyme replacement therapy in patients with Gaucher disease.
Séllos-Moura M; Barzegar S; Pan L; Shi P; Oommen S; Durant J; Ruiz JA
J Immunol Methods; 2011 Oct; 373(1-2):45-53. PubMed ID: 21846471
[TBL] [Abstract][Full Text] [Related]
13. How we manage Gaucher Disease in the era of choices.
Revel-Vilk S; Szer J; Mehta A; Zimran A
Br J Haematol; 2018 Aug; 182(4):467-480. PubMed ID: 29808905
[TBL] [Abstract][Full Text] [Related]
14. Large soft-tissue masses in an adult patient with Gaucher disease.
Mahajan N; Brynes R; Yano S
J Inherit Metab Dis; 2016 Nov; 39(6):887-888. PubMed ID: 27503099
[TBL] [Abstract][Full Text] [Related]
15. Enzyme replacement therapy for Gaucher disease.
Beutler E; Kay A; Saven A; Garver P; Thurston D; Dawson A; Rosenbloom B
Blood; 1991 Sep; 78(5):1183-9. PubMed ID: 1878585
[TBL] [Abstract][Full Text] [Related]
16. Taliglucerase alfa in Gaucher disease: Description of a Brazilian experience.
Cravo R; Rotman V; Oliveira PMN; Defendi HGT; Conceição DA; Xavier JR; Chertkoff R; Noronha TG; Maia MLS
Blood Cells Mol Dis; 2018 Feb; 68():160-162. PubMed ID: 28131618
[TBL] [Abstract][Full Text] [Related]
17. Combined miglustat and enzyme replacement therapy in two patients with type 1 Gaucher disease: two case reports.
Amato D; Patterson MA
J Med Case Rep; 2018 Jan; 12(1):19. PubMed ID: 29373994
[TBL] [Abstract][Full Text] [Related]
18. Gaucher Disease: Clinical, Biological and Therapeutic Aspects.
Dandana A; Ben Khelifa S; Chahed H; Miled A; Ferchichi S
Pathobiology; 2016; 83(1):13-23. PubMed ID: 26588331
[TBL] [Abstract][Full Text] [Related]
19. Cellular Uptake of Glucocerebrosidase in Gaucher Patients Receiving Enzyme Replacement Treatment.
Gras-Colomer E; Martínez-Gómez MA; Moya-Gil A; Fernandez-Zarzoso M; Merino-Sanjuan M; Climente-Martí M
Clin Pharmacokinet; 2016 Sep; 55(9):1103-13. PubMed ID: 27083470
[TBL] [Abstract][Full Text] [Related]
20. Gaucher disease.
Mignot C; Gelot A; De Villemeur TB
Handb Clin Neurol; 2013; 113():1709-15. PubMed ID: 23622393
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
